Stay updated with breaking news from Eric Simpson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NEW ORLEANS — Patients with hand and foot atopic dermatitis experienced significant improvement with dupilumab, which sustained an acceptable safety profile, according to phase 3 study results presented here. “These results are the first to highlight how Dupixent can improve signs and symptoms of atopic hand and foot dermatitis, which is very difficult to treat,” Eric Simpson,
/PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announces that data from the Phase 2b study of rocatinlimab (KHK4083/AMG 451), an investigational...
OHSU researchers have worked to reduce barriers such as language and lack of transportation to increase participation.
Hartley's new Fellrunners beer had people scampering back to the bar for more in 1988.
The results of pooled safety data for Adbry showed positive effects in the prolonged treatment of moderate to severe atopic dermatitis, according to a study. Adbry (tralokinumab, LEO Pharma) is the only FDA-approved biologic that specifically binds to and inhibits the interleukin (IL)-13 cytokine, one of the drivers of atopic dermatitis.